THE ROLE OF PNL2 MONOCLONAL ANTIBODIES IN THE DIAGNOSIS OF MELANOMA
Keywords:
malignant melanoma, PNL2, immunohistochemistry, C-100, HMB45, Melan-A, mucosal melanoma, biomarkers.Abstract
Malignant melanoma (MM) has high aggressiveness and is difficult to diagnose, especially in amelanotic, acral, mucosal, and metastatic forms, due to morphological similarities. Immunohistochemistry (IHK) is the main auxiliary method in these cases. Such markers as C-100, HMB45, Melan-A/MART-1, tyrosinase, MITF are widely used, however, each of them has limitations in sensitivity or specificity. PNL2 is a new monoclonal antibody of the melanocytic orientation, which has practical significance due to the recognition of a stable antigen in formalin-paraffin blocks, staining melanin even after "bleaching" and decalcification. The high sensitivity of PNL2 in melanoma of the mucous membrane, its higher specificity to S-100, and its role in reducing diagnostic errors in the composition of the marker panel are highlighted.
References
Rochaix P, Lacroix-Triki M, et al. PNL2, a new monoclonal antibody directed against a fixative-resistant melanocyte antigen. Modern Pathology. 2003.
Morris, L.G., et al. PNL2 melanocytic marker in immunohistochemical diagnosis of head and neck mucosal melanoma. [PubMed indexed] 2008.
Giudice, C. et al. Immunohistochemical investigation of PNL2 reactivity of canine melanocytic neoplasms and comparison with Melan A. 2010.
Yu CH, et al. HMB-45 may be a more sensitive marker than S-100 or Melan-A for immunohistochemical diagnosis of primary oral and nasal mucosal melanoma. 2005.
Ricci C, et al. Skin melanoma: review on immunohistochemistry in diagnosis and characterization. International Journal of Molecular Sciences. 2022.
Shinohara M, et al. S100, HMB-45, and Melan-A negative primary melanoma (case report). 2009.
Ramos-Vara JA, et al. Immunohistochemical expression of melanocytic antigen markers and notes on PNL2 sensitivity/specificity. 2014.
Quilaqueo N, et al. Immunohistochemical markers S-100, HMB-45, MART-1 in differential diagnosis of melanoma and nevi. 2021.
Bolovan L.M., et al. Correlation studies between soluble S100B/MIA and tissue melanocytic markers (S100, gp100/HMB45, MelanA). 2023.
Sigma-Aldrich. Anti-PNL2 monoclonal antibody product background and cited performance notes (metastatic melanoma sensitivity data cited in product literature).
Azerbaijan
Türkiye
Uzbekistan
Kazakhstan
Turkmenistan
Kyrgyzstan
Republic of Korea
Japan
India
United States of America
Kosovo